IL153497A0 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Info

Publication number
IL153497A0
IL153497A0 IL15349701A IL15349701A IL153497A0 IL 153497 A0 IL153497 A0 IL 153497A0 IL 15349701 A IL15349701 A IL 15349701A IL 15349701 A IL15349701 A IL 15349701A IL 153497 A0 IL153497 A0 IL 153497A0
Authority
IL
Israel
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Application number
IL15349701A
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153497A0 publication Critical patent/IL153497A0/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
IL15349701A 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition IL153497A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (1)

Publication Number Publication Date
IL153497A0 true IL153497A0 (en) 2003-07-06

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15349701A IL153497A0 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (en)
JP (1) JP2004501190A (en)
KR (1) KR20030013460A (en)
AU (2) AU2001268722B8 (en)
CA (1) CA2412490A1 (en)
CZ (1) CZ2003199A3 (en)
EA (1) EA200300046A1 (en)
HU (1) HUP0301465A3 (en)
IL (1) IL153497A0 (en)
MX (1) MXPA02012793A (en)
WO (1) WO2002000213A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
IL160363A0 (en) * 2001-08-16 2004-07-25 Oregon State Expandable gastric retention device
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1615632B1 (en) * 2003-04-17 2006-12-06 Jallal Messadek Floating oral formulations for controlled release of betaine
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
JP2005132803A (en) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd Solid pharmaceutical preparation staying in stomach
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
MX2007013486A (en) 2005-04-27 2008-03-14 Jallal Messadek Insulins combinations.
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
UA95954C2 (en) * 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Long term 24 hour intestinal administration of levodopa/carbidopa
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
CL2007002574A1 (en) * 2006-09-08 2008-05-23 Drug Tech Corp Sa Organizada B ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
CA2673485A1 (en) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-release preparation containing cilostazol and process for the preparation thereof
DE102007026037A1 (en) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN102076215A (en) 2008-06-30 2011-05-25 托卡根公司 Formulations of 5-fluorocytosine and uses thereof
AU2009281752B2 (en) 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2012093974A1 (en) * 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (en) * 2012-05-07 2017-06-23 新疆医科大学 Benserazide micro-capsule floating tablet
WO2013183058A2 (en) 2012-06-07 2013-12-12 Tulip Medical Ltd. Expanded device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (en) * 2013-04-22 2017-09-27 テイカ製薬株式会社 Oral rapidly disintegrating composition for solid preparation
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2015083171A1 (en) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
AU2016225052B2 (en) * 2015-02-27 2021-07-08 Cingulate Therapeutics LLC Tripulse release stimulant formulations
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
ES2928071T3 (en) 2017-06-16 2022-11-15 Amneal Complex Products Res Llc Gastroretentive dosage forms for sustained drug delivery
JP7048770B2 (en) 2018-06-18 2022-04-05 アムニール コンプレックス プロダクツ リサーチ エルエルシー Sustained release composition containing pyridostigmine
DK3628004T3 (en) 2018-06-27 2021-12-20 Amneal Complex Products Res Llc Self-regulating osmotic gastrointestinal restraint drug delivery systems
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2021176360A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Oral dosage forms for extended drug release
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
AU8578498A (en) * 1997-07-23 1999-02-16 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Also Published As

Publication number Publication date
EP1305021A1 (en) 2003-05-02
EP1305021A4 (en) 2009-09-23
KR20030013460A (en) 2003-02-14
HUP0301465A3 (en) 2006-07-28
MXPA02012793A (en) 2004-07-30
HUP0301465A2 (en) 2004-05-28
WO2002000213A1 (en) 2002-01-03
AU6872201A (en) 2002-01-08
EA200300046A1 (en) 2003-10-30
CA2412490A1 (en) 2002-01-03
AU2001268722B8 (en) 2005-09-29
AU2001268722B2 (en) 2005-08-11
CZ2003199A3 (en) 2003-12-17
JP2004501190A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
HK1060305A1 (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (en) Controlled release hydrocodone formulations.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
EP1257255A4 (en) Therapeutic product, use and formulation thereof
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
GB0002386D0 (en) Therapeutic composition
FI20000780A (en) Oral dosage form for controlled release of the drug
MXPA03004303A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain.
EP1501352A4 (en) Methods and compositions for controlled release of drugs
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
GB0030067D0 (en) Therapeutic agent
EP1357898A4 (en) Improved controlled release oral dosage form
HK1046848A1 (en) Specific therapeutic composition for treating aids
HK1055954A1 (en) Crystalline therapeutic agent.